Articles

• Rationale for transdermal drug administration in Alzheimer disease

  Wolfgang Oertel, Joel S. Ross, Karla Eggert, Georg Adler

  • Abstract
  • Full Text
  • Full Text (PDF)
• Pharmacokinetic rationale for the rivastigmine patch

  Jeffrey Cummings, Gilbert Lefèvre, Gary Small, Silke Appel-Dingemanse

  • Abstract
  • Full Text
  • Full Text (PDF)
• IDEALA 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease

  B. Winblad, G. Grossberg, L. Frölich, M. Farlow, S. Zechner, J. Nagel, R. Lane

  • Abstract
  • Full Text
  • Full Text (PDF)
• Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease

  Rafael Blesa, Clive Ballard, Jean-Marc Orgogozo, Roger Lane, Simu K. Thomas

  • Abstract
  • Full Text
  • Full Text (PDF)